Nymox Announces New Positive Results from 3 1/2 Year Study of NX-1207 for Benign Prostatic Hyperplasia

11-May-2007

Nymox Pharmaceutical Corporation announced positive results from a new long-term outcome study of NX-1207 for benign prostatic hyperplasia (BPH). The study evaluated symptomatic progress of U.S. patients involved in the Company's two Phase 1-2 studies initiated in 2003. Patients treated with NX-1207 were followed-up on an unselected and as available basis and assessed for symptomatic improvement, treatment outcomes, and durability of efficacy 3 1/2 years after NX-1207 treatment.

Overall, patients treated with NX-1207 showed a mean improvement of 8.6 points in the primary outcome endpoint of AUA Symptom Score value 42 months after NX-1207 treatment. 50% of these patients reported no additional treatment for the BPH during this period and had a mean improvement of 10.0 points in AUA Symptom Score. This sustained improvement in BPH symptom score after NX-1207 treatment compares favorably to the 3.5 to 5 points reported in published studies of currently approved BPH drugs, which, unlike NX-1207 treatment, require uninterrupted, daily administration to be effective.

Paul Averback, CEO of Nymox, said, "This new data on NX-1207 showing sustained symptomatic improvement after 3 1/2 years clearly confirms the enduring benefits of NX-1207 treatment for BPH."

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances